Key result
An audit of patients with type 2 diabetes revealed poor adherence to chronic kidney disease screening guidelines, with urinalysis performed in 49.1% and serum creatinine in 50.3%.
Observational (n=169)
There is poor adherence to clinical guidelines for chronic kidney disease screening and renoprotection among patients with type 2 diabetes in routine practice.
Highlights gaps in diabetes CKD screening; leaves open optimal implementation strategies and barriers.
BACKGROUND: Type 2 diabetes (T2D) is a major cause of chronic kidney disease. Control of hypertension and the use of angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II receptor blockers especially in those with proteinuria have been shown to protect against chronic kidney disease and delay its progression to kidney failure. METHODS: We reviewed the medical records of 169 patients at 12 months with a view of auditing the screening for chronic kidney disease and the use of renoprotective measures. RESULTS: Urinalysis was done in 49.1% and serum creatinine in 50.3%. No patient had glomerular filtration rate estimated. Seventy nine (67.6%) of the hypertensive patients were on anti-hypertensives. ACEI was used in 49 (45.8%) of these patients BP control was optimal in 29.1%. CONCLUSION: There is poor adherence to guidelines on chronic kidney disease screening and renoprotection in T2D.
No takes yet. Share an insight, caveat, or question.
Agaba et al. (2009) conducted an observational in Type 2 diabetes (n=169). Chronic kidney disease screening and renoprotective measures was evaluated on Adherence to chronic kidney disease screening and renoprotection guidelines. An audit of patients with type 2 diabetes revealed poor adherence to chronic kidney disease screening guidelines, with urinalysis performed in 49.1% and serum creatinine in 50.3%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: